Neglected tropical diseases such as Leishmaniasis and Chikungunya fever are worldwide public health challenges mainly affecting tropical and subtropical countries. One cationic [Cu-(I)(NHC) 2 ] + (4) and two neutral [Cu(I)(NHC)Cl] complexes, where NHC = 1,3-bis(mesityl)imidazole-2-ylidene (IMes) (5) or 1,3-bis-(2,6-diisopropylphenyl)imidazole-2-ylidene (IPr) (6), had their in vitro activity evaluated towards Leishmania amazonensis and Chikungunya virus (CHIKV). The compound (6) inhibited 95 % of L. amazonensis infection in RAW macrophages at 10 μM and 90 % of the CHIKV replication at 2 μM in BHK-21 cells. Otherwise, the other compounds showed higher cytotoxicity in BHK-21 and RAW or lower antiparasitic or antiviral activities.The best activity of compound 6 can be explained by slower ligand exchange with solvent molecules measured by 1 H NMR technique and the best hydrophilic/lipophilic balance (log P = À 0.684 � 0.055) in the series determined by shake flask method. Antioxidant activity measured by reduction of DPPH revealed a moderate redox ability of all complexes. The binding constant of ( 6) with bovine serum albumin (BSA) represents the weakest in the series (10 3 ). The chemical and in vitro evaluation reported here represent a novel application and chemical insights for the design of [Cu(I)(NHC)L] metallodrugs for these infectious diseases.